FDA Clears First OTC CGM Device for Diabetes Management and Prevention

FDA Clears First Over-the-Counter Continuous Glucose Monitor

The U.S. Food and Drug Administration cleared the Dexcom Stelo Continuous Glucose Monitoring System on March 5, 2024. This marks the first time the agency authorized a continuous glucose monitor for sale without a prescription. The device is indicated for adults 18 years and older who do not take insulin. The clearance rests on performance data from a predicate device and aligns with federal resources that outline glucose monitoring as part of diabetes self-management. [1][2][3]

What this means

The clearance moves one CGM product into retail channels. Adults who match the indicated group can now access sensor readings every 15 minutes through a smartphone app without first obtaining a prescription. This development corresponds to CDC and NIDDK materials that discuss monitoring strategies for the large share of people with diabetes who do not use insulin. [2][3]

Key takeaways

• The FDA cleared the Dexcom Stelo as the first over-the-counter continuous glucose monitor on March 5, 2024. [1]
• The system is indicated for adults 18 years and older who do not take insulin. [1]
• It measures glucose in interstitial fluid every 15 minutes, sends results to a smartphone app, and allows the sensor to be worn for up to 15 days. [2]
• The device is not authorized for people who take insulin, individuals under age 18, or for diagnosing diabetes. [1]
• Clearance relied on predicate device data, and long-term population-level outcomes for OTC use are still emerging. [1]

The FDA reviewed performance metrics for safety and accuracy in the stated population. [1] NIDDK materials note that CGM technology can show glucose patterns that single blood tests may miss. [2] CDC guidance lists glucose monitoring as one element of diabetes self-management. [3]

Device functionality

The sensor sits on the skin and reads glucose from interstitial fluid. Results transfer automatically to the user's smartphone every 15 minutes. Each sensor lasts up to 15 days before replacement. [2]

Indications and restrictions

FDA documents list clear boundaries for the Stelo system. It carries approval only for adults 18 and older who do not use insulin. The product is not indicated for diabetes diagnosis, for anyone under 18, or for use during pregnancy. [1]

Limitations

The device was not studied or authorized for people taking insulin. It carries no authorization for use in pregnancy or in individuals under 18 years of age. CGM readings can lag behind blood glucose values, so confirmation with fingerstick tests may be needed when symptoms do not match the app. Clearance is based on predicate device performance. Long-term population-level outcomes data for OTC use are still emerging. [1][2]

FAQ

What are the indications, contraindications, and usage limitations for the Dexcom Stelo OTC CGM?
It is indicated for adults 18 and older who do not take insulin. It is not for insulin users, people under 18, pregnant individuals, or for diabetes diagnosis. Readings may lag behind blood glucose and should be confirmed with fingerstick tests when symptoms differ. [1][2]

How does OTC availability of a CGM change access and diabetes management compared to prescription-only devices?
The clearance removes the prescription barrier that previously applied to all CGMs. This expands access for adults managing glucose levels without insulin therapy. The device still does not replace professional medical advice or more intensive monitoring needs. [1][3]

What evidence or data supported the FDA's clearance decision for over-the-counter marketing?
The agency reviewed data from a predicate device with established performance. Officials determined the system met standards for safety and effectiveness in the stated adult population not using insulin. Long-term outcomes data specific to unrestricted OTC sale continue to develop. [1]